MA56548A - Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation - Google Patents

Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation

Info

Publication number
MA56548A
MA56548A MA056548A MA56548A MA56548A MA 56548 A MA56548 A MA 56548A MA 056548 A MA056548 A MA 056548A MA 56548 A MA56548 A MA 56548A MA 56548 A MA56548 A MA 56548A
Authority
MA
Morocco
Prior art keywords
mage
methods
lymphocyte receptors
lymphocyte
receptors
Prior art date
Application number
MA056548A
Other languages
English (en)
Inventor
Natalie Bowerman
Cagan Gurer
Johanna Hansen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56548A publication Critical patent/MA56548A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
MA056548A 2019-06-18 2020-06-17 Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation MA56548A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862726P 2019-06-18 2019-06-18
US201962871793P 2019-07-09 2019-07-09

Publications (1)

Publication Number Publication Date
MA56548A true MA56548A (fr) 2022-04-27

Family

ID=74040867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056548A MA56548A (fr) 2019-06-18 2020-06-17 Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation

Country Status (15)

Country Link
US (1) US20220324939A1 (fr)
EP (1) EP3986938A4 (fr)
JP (3) JP7730765B2 (fr)
KR (1) KR20220035387A (fr)
CN (2) CN118994364A (fr)
AU (1) AU2020295401A1 (fr)
BR (1) BR112021025548A2 (fr)
CA (1) CA3144253A1 (fr)
CL (2) CL2021003366A1 (fr)
CO (1) CO2022000281A2 (fr)
IL (1) IL289042A (fr)
MA (1) MA56548A (fr)
MX (1) MX2021015946A (fr)
PH (1) PH12021553152A1 (fr)
WO (1) WO2020257288A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG11201901634UA (en) * 2016-09-23 2019-04-29 Lion Tcr Pte Ltd An hbv antigen specific binding molecules and fragments thereof
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
EP4422651A4 (fr) * 2021-10-25 2025-12-17 Univ Texas Peptides et récepteurs de lymphocytes t modifiés ciblant l'antigène mage-a4 et méthodes d'utilisation
EP4472742A1 (fr) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Nouveau récepteur des lymphocytes t
WO2023238125A1 (fr) * 2022-06-08 2023-12-14 Sheba Impact Ltd. Récepteurs de lymphocytes t recombinés spécifiques d'un virus et lymphocytes t les contenant
JP2025525382A (ja) * 2022-06-24 2025-08-05 アムジエン・インコーポレーテツド Ｍａｇｅａ４特異的ｔ細胞受容体
CA3264474A1 (fr) 2022-09-14 2024-03-21 Cdr-Life Ag Engagement de lymphocytes t doubles de peptide mage-a4
JP2026509947A (ja) 2022-10-31 2026-03-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法
EP4393942A1 (fr) * 2022-12-29 2024-07-03 Keshihua (Nanjing) Biotechnology Co., Ltd Tcr, polypeptide, vecteur d'expression, cellule hôte, composition pharmaceutique et procédé d'obtention de tcr
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN119569851A (zh) * 2023-09-05 2025-03-07 香雪生命科学技术（广东）有限公司 针对magea4的高亲和力tcr
WO2025233432A1 (fr) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Utilisation et dosage d'une protéine de liaison à l'antigène comprenant un tcr spécifique d'un peptide restreint par hla-a*02

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SMT202200306T1 (it) * 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
BR112018070637A2 (pt) * 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
WO2020243134A1 (fr) 2019-05-27 2020-12-03 Immatics US, Inc. Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof

Also Published As

Publication number Publication date
PH12021553152A1 (en) 2022-08-15
JP2024164066A (ja) 2024-11-26
KR20220035387A (ko) 2022-03-22
CN118994364A (zh) 2024-11-22
JP2022537359A (ja) 2022-08-25
CN114585646A (zh) 2022-06-03
JP7730765B2 (ja) 2025-08-28
WO2020257288A2 (fr) 2020-12-24
BR112021025548A2 (pt) 2022-05-17
CA3144253A1 (fr) 2020-12-24
US20220324939A1 (en) 2022-10-13
CN114585646B (zh) 2024-09-03
CL2021003366A1 (es) 2022-08-19
IL289042A (en) 2022-02-01
EP3986938A2 (fr) 2022-04-27
JP2025166209A (ja) 2025-11-05
AU2020295401A1 (en) 2022-02-10
WO2020257288A3 (fr) 2021-04-08
EP3986938A4 (fr) 2023-06-28
CO2022000281A2 (es) 2022-01-28
CL2024000119A1 (es) 2024-05-31
MX2021015946A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
MA56548A (fr) Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation
MA53981A (fr) Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation
EP3947688A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3935172A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3737689A4 (fr) Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
EP3935176A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3436079A4 (fr) Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3935079A4 (fr) Polypeptides de présentation d'antigènes modulateurs de lymphocytes t et leurs procédés d'utilisation
EP3565829A4 (fr) Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
EP3935171A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
MA56191A (fr) Inhibiteurs de l'autophagie à base d'amide d'aminopyrimidine et leurs procédés d'utilisation
EP3897701A4 (fr) Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
EP4072576A4 (fr) Orthologues de l'il-2 et procédés d'utilisation
MA47265A (fr) Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3423108A4 (fr) Polypeptides multimères modulateurs des lymphocytes t et leurs procédés d'utilisation
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3873939A4 (fr) Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation
EP4153618A4 (fr) Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation
EP4003378A4 (fr) Banques de lymphocytes t spécifiques de l'antigène et leurs procédés de fabrication et d'utilisation thérapeutique
EP4048402A4 (fr) Lymphocytes t cytoxiques modifiés et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3765070A4 (fr) Cellules spécifiquement modifiées, anticorps de modulation immunitaire de lymphocytes t et leurs procédés d'utilisation